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S. Craig 
PURINE SALVAGE ENZYMES AS TARGETS 
FOR THE CHEMOTHERAPEUTIC TREATMENT 
OF PARASITIC DISEASES 
The review analyses the results showing that technological advances in studying the spe­
cific target molecules in a cell allow to develop new effective drugs for the treatment of 
a number of human maladies. The new approach to the drug design is based In the data 
of enzyme structure. 
Rational drug discovery/desing. The traditional approach to the discovery 
of new drugs has involved the screening of large numbers of compounds 
or extracts for bioactivity against specific pathogens. This more or less 
random approach has usually been conducted without knowledge of the 
molecular targets within the pathogen or mode of action of the drugs. 
Host toxicity is usually determined empirically, only after a bioactive sub­
stance has been identified. 
Another, more systematic approach to drug discovery begins with the 
identification of a molecular target within the pathogenic organism. Tar­
gets are usually selected because their functions are pivotal for survival 
and thus, inhibition of those functions may be lethal for the pathogenic 
organism. Appropriate targets may be either enzymes that catalyze uni­
que metabolic pathways or enzymes that are present in both the host and 
the pathogen. In the latter case, the enzymes may be pivotal only for 
survival of the pathogen, or they might be of equal importance for both 
the host and pathogen but are suitable targets because of differences in 
the pharmacological responses to specific drugs. For all of these situati­
ons, after the target molecule has been selected, the objective is to identi­
fy details of molecular structure and/or function that can be exploited in 
the discovery or design of low molecular weight compounds that will se­
lectively bind to the target molecule of the pathogen. Well-designed com­
pounds should be highly selective in their affinity for the target molecule 
of the pathogen, as compared to molecules of the host and thus may be 
used at therapeutic levels that are non-toxic to the host. 
Technological approaches to rational drug desing. If a target mole­
cule is an enzyme, traditional biochemical procedures are appropriate for 
analyzing enzyme/drug interactions. For example, kinetic studies of the 
affects of various concentrations of a drug as an inhibitor of the initial 
velocity of an enzyme catalyzed reaction, provide information about whe­
ther a compound competes for binding to the active site of an enzyme or 
an enzyme substrate complex [1]. Such information can be useful for 
the design of novel inhibitors. Furthermore, steady state kinetic studies 
can enable the determination of the concentration for a compound (Ki) 
at which half of the enzyme should be bound to the compound. This con­
centration is directly related to the affinity of the compound for the tar­
get molecule and is the minimum concentration that might be expected 
to have any possibility of partially blocking the enzyme catalyzed reacti­
on believed to be pivotal for the survival of the pathogenic organism. Al­
though KiS can be determined using impure enzyme, this value, determined 
in vitro, can be more than an order of magnitude below that required in 
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vivo to kill half of the pathogenic organisms [2]. However, KiS provide 
physical constants for quantitating the selective affinity of compounds for 
the target enzyme of a pathogen, as opposed to the homologous enzyme 
of a host organism. For enzymes that are unique to a pathogen, the Ki 
provides a minimum concentration for testing the in vivo effectiveness 
and pharmacological properties of a compound. 
Enzyme structure based drug design utilizes structural details to 
design inhibitors selective for the enzyme of the pathogen. By definition, 
the determination of three-dimensional structure of the target enzyme is 
necessary. This can require the purification of milligram quantities of 
the target enzymes from both the host and the pathogen. Since many tar­
get molecules are in relatively low abundance within the cells of the host 
or pathogen, purification of these molecules from the native source is 
often impractical. However, developments in molecular biology have enab­
led the cloning of cDNA and the expression of high levels of enzymes 
within bacteria, yeast, or insect cells. For example, at present, it is possib­
le to produce recombinant enzymes at 20—60 % of the total soluble pro­
teins in bacteria [3—6]. Thus, the acquisition of quantities of protein ade­
quate for structural analysis (i. e. via NMR or X-ray crystallography) 
is less problematical today than it has been in the recent past. 
Selective inhibitors (often referred to as «lead compounds» or «le­
ads») having, an affinity for a target enzyme may already be known. How­
ever, even if «leads» have not formerly been identified, three-dimensio­
nal structure provides physical data that can be exploited, using compu­
ters and computational chemistry, in the selection of compounds that may 
bind to the active site of an enzyme, from among thousands of commer­
cially available compounds [7]. Occassionally, the target enzyme may be 
similar enough to a related enzyme whose structure is known to enable 
the use of a model of the enzyme's structure rather than the actual 3-di-
mensional structure for the computer based selection of new leads [8]. 
Empirical testing (kinetic studies as described above) will demonstrate 
if any of these compounds are good «leads» with an affinity for the active 
site of the target enzyme. Also, co-crystallization of the lead compounds 
with the target enzymes of both the host and the pathogen enables three 
dimensional analyses and the determination of molecular contacts and 
atomic interactions between the lead compounds and the target enzymes. 
This type of analysis may reveal differences in the enzymes of the host 
and pathogen that can be exploited in the re-design of leads to enhance 
their affinity for the target enzyme of the pathogen [9—11]. Thus, itera­
tive crystallography, lead re-design, and inhibitor testing both in vitro and 
in vivo can enable the design of a potent selective inhibitor of a target 
enzyme of a pathogen. In theory, inhibitors designed this way have a 
better chance for being developed as an effective and non toxic agent 
for the treatment of the disease caused by the pathogen. 
Molecular targets of paiasites for rationally designed drugs. The 
vast majority of drugs in use today, for the treatment of diseases caused 
by parasites, were identified by traditional methods requiring the random 
screening of large numbers of compounds for bioactivity against the pa­
rasites. Subsequently, the molecular targets of a few of these drugs have 
been determined. For example, dihydrofolate reductase (DHFR) has been 
shown to be the target of compounds used in the treatment of a number 
of diseases. Several compounds, such as chloroguanide, pyrimethamine, 
and trimethoprim, which bind to DHFR's are in therapeutic use for the 
treatment of diseases caused by parasites [12]. Furthermore, various 
other antifolates are being tested for the treatment of infections caused 
by Pneumocystis carinii [13—14] and Toxoplasma gondii [13, 15]. These 
two infectious agents are increasingly important because they often are 
problematical for immunocompromised patients suffering from AIDS or 
recovering from an organ transplant. Also, antifolates are used for the 
treatment of Plasmodium falciparum, an etiologic agent for malaria [12, 
16]. In^ addition to DHFR, other molecular targets have been identified 
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for drugs used in the treatment of parasitic diseases. These include the 
ornithine decarboxylase of trypanosomes [17] and the heme polymerase 
of malarial parasites [18—19]. Rational approaches to drug discovery 
and design, as described above, can and are being emploved to discover* 
novel, potent, nootoxic compounds that will be more effective than exis* 
ting approved drugs for the treatment of diseases caused by parasites. 
Purine salvage enzymes as a target for rational drug discovery/de-
sing. Due to their pivotal role for the survival of parasites, purine salvage 
enzymes were proposed more than 25 years ago as potential targets for 
the chemotherapeutic treatment of malaria [20, 21]. However, unlike 
DHFR, purine salvage enzymes have yet to be demonstrated to be the tar­
get of an approved drug used in the treatment of a disease caused by a 
pathogen. During the past two decades, the purine salvage enzymes of a 
number of different parasites have been investigated. These studies in­
clude enzymes from the etiologic agents for human leishmaniasis [22],. 
giardiasis [23], Chagas' disease [24], and schistosomiasis [25], as well 
as bovine tritrichomoniasis [26]. These studies show that the parasites 
examined lack the anabolic pathways needed for the de novo synthesis of 
purines. Thus, these organisms are forced to rely exclusively upon salvage' 
pathways for the purines [guanosine triphosphate (GTP) and adenosine 
triphosphate (ATP)] needed in RNA and DNA synthesis and for high 
energy phosphate bonds to drive cellular metabolism. 
Hypoxanthine phosphoribosyltransferase [HPRT; IMP: pyrophosp­
hate phosphoribosyltransferase, ES 2.4.2.8, also hypoxanthine-guanine 
phosphoribosyltransferase (HGPRT) or hypoxanthine-guanine-xanthine 
phosphoribosyltransferase (HGXPRT)] is. a purine salvage enzyme that 
has been studied extensively. Complementary DNA (cDNA) encoding the 
human, schistosomal, malarial, trypanosomal, tritrichomonal, and bacte­
rial HPRT's have been cloned and sequenced ([27—32], respectively). 
The human HPRT has been a subject of extensive investigation because 
defects in this enzyme are known to be responsible for genetically inhe­
rited gout and Lesch—Nyhan syndrome in humans [33, 34]. The symp­
toms of these diseases, which range from deleterious to lethal, result 
from inactivation of the human enzyme. This emplasizes the importance 
of trying to minimize the interactions of drugs with the HPRT of mamma­
lian hosts. 
Leads for drugs targeted to HPRTs. The long range objective of the 
majority of the investigations of parasite purine salvage pathways is to 
discover or design compounds that will selectively inhibit the activity of 
a pivotal enzyme. The hope is that such a compound could be developed 
as a drug in the treatment of the parasitic disease. However, only in re­
cent years has significant progress been made toward the identification 
of lead compounds that selectively target the purine salvage ensvmes of 
any parasite [2, 22, 35]. 
Allopurinol is a relative non-toxic analog of xanthine that is approved 
for use in the treatment of gout in humans. In humans the target of allo­
purinol is the xanthine oxidase enzyme which converts xanthine to uric 
acid. Allopurinol has also been shown to kill leishmanial parasites [36]. 
The drug is salvaged by the PHRT enzyme into the nucleotide pools and 
is eventually incorporated into RNA which leads indirectly to an inhibi­
tion of protein synthesis. This mechanism is postulated to account for the 
antiparasitic action of allopurinol [36]. Thus, allopurinol is probably ef­
fective in the treatment of Leishmaniasis because it is salvaged and incor­
porated into RNA by the parasite but not by the host. These results show 
promise that other substrate analogs, that will selectively bind to the 
HPRTs of parasites, might be designed or discovered. 
Queen et al. [2] demonstrated that 6-mercaptopurine (an analog of 
hypoxanthine) and 6-thioguanine were «potent competitive inhibitors» of 
the malarial HPRT. Six-mercaptopurine is metabolized to 6-thiouric acid 
(6-mercapto-2,8-purinediol) in humans [37]. Both 6-mercaptopurine and 
6-thioguanine have been used therapeutically as antineoplastics in humans 
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[37]. Kinetic studies indicate that both of these compounds may be slight­
ly selective in their inhibition of the malarial HPRT as opposed to the 
human enzyme. Thus, these compounds may be good leads for drugs tar­
geted to the HPRT of parasites responsible for human malaria. 
Recently, a new method has been reported for screening for leads 
targeted to the HPRT's of parasites [35]. This method is referred to as 
comparative complement selection and involves the rapid screening in 
bacteria of purine analogs for the inhibition of the recombinant HPRT's 
of parasites as compared to the recombinant human enzyme. The proce­
dure uses the activity of a recombinant HPRT to complement genetic de­
ficiencies of the host bacteria. The bacteria are unable to grow unless 
they are expressing a recombinant HPRT. Thus, the effects of compounds 
on the growth of these bacteria can be screened employing sterile, blank 
antibiotic testing discs and methods similar to those used in standard 
antibiotic susceptibility assays. Complement selection alone enables the 
identification of compounds that affect the growth of bacteria expressing 
a particular enzyme. However, direct comparisons with the effects on bac­
teria expressing the recombinant human enzyme enable the identification 
of compounds that selectively target the enzymes of the parasites. 
Three-dimensional analysis: a prerequisite to enzyme structure based 
drug design. Since most HPRT's are functional as dimers, with molecular 
weights in excess of 40 kDa, the only practical method for determining 
three-dimensional structure requires crystallization followed by analyses 
of X-ray diffraction patterns. As of this date, the three dimensional struc­
ture for a purine salvage enzyme has yet to be reported in the literature, 
although the structure of orotate phosphoribosyltransferase, a distantly 
related enzyme, was recently reported [38]. However, several laboratori­
es are actively working on the structure for a number of different HPRT's. 
For example, crystals which diffract X-ray to a resolution of less than 
3 A have been generated for both the human and schistosomal HPRT's 
(Focia' and Fletterick, personal communication). Thus, the structures of 
several HPRT's may be available in the not too distant future. As soon 
as these structures are available, will be possible to analyze the binding 
of «lead compounds» identified in the complement selection assay and 
to move directly into the next phase of enzyme structure based inhibitor 
design and refinement. 
The development of resistance to new drugs. Microbial pathogens, 
including parasites, are notorious for their ability to develop resistance 
to drugs. It is for this reason that so much effort is being directed today 
i.toward the development of vaccines for the treatment of parasitic disea­
ses. However, parasites seem to be extraordinarily adapted to surviving 
the immune responses of their hosts. This helps to explain why there is 
still not a single, completely effective vaccine in use today for the treat­
ment of parasitic disease of humans. 
The advantage of the rational approach to the discovery or design of 
new drugs, over the traditional random screening method, is that the 
target of the drug is known. If the target is an enzyme, it will need to 
be cloned and expressed to enable 3-dimensional and kinetic studies. Thus, 
even before a single new drug has been discovered, there is an normous 
side benefit that will enable the rapid development of second generation 
drugs to treat first generation drug-resistant strains that may appear in 
the future. Specifically, PCR primers can be designed that will enable 
the amplification and re-cloning of cDNA encoding the target enzyme of 
drug resistant strains using available technology [39]. The sequence for 
cDNA may immediately reveal point mutations and amino acid substitu­
tions in the target enzyme that are responsible for the resistance to the 
new drugs [16, 40]. The amino acid substitution (s) can be analyzed using 
the known 3-dimensional structure for the target enzyme and interactive 
computer graphic display systems to reveal the mechanism for alteration 
of the binding of the drug to the active site of the enzyme. This infor­
mation may reveal how the drug could be modified to yield a second ge-
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neration drug for the treatment of the resistant strains of the 
pathogen. 
This process does not need to await the appearance of resistant stra­
ins in the wild. Instead, drug resistant strains can be generated in patho­
gens cultured in vitro, under the pressure of low concentrations of the 
new drug. The development of resistance to the new drug can be analy­
zed as described above and mutations involving the target enzyme can be 
identified [41]. By this means, second generation drug can be designed 
to treat some of the possible resistant forms of a pathogen, even before 
they have occurred in the wild. 
Closing. The promises of rational drug discovery/design have long 
been debated. However, technological advances have finally brought us 
to the point where enzyme structure based drug design can facilitate the 
development of new drugs for the treatment of a number of human mala­
dies [8, 42—44]. 
С. Крег 
ФЕРМЕНТИ ДОДАТКОВОГО ШЛЯХУ СИНТЕЗУ ПУРИН1В — М>1ШЕНЬ 
ДЛЯ ХГМЮТЕРАПЕВТИЧНОГО Л1КУВАННЯ ПАРАЗИТАРНЫХ ХВОРОБ 
Р е з ю м е 
В отлялх проаналйзовано результаты, як! показують, що досягнення у вивченш специ­
фичных молекул-мшеней юптини дозволяють розробляти ефективш лжарсыа засоби 
для лжування багатьох захворювань людини. Встановлено, що новий шдх!д до роз,-
робки таких медикаментов базуеться на дослщженш структури молекули фермента. 
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